Published in Clin Cancer Res on September 24, 2013
4SC-201 (Resminostat) in Advanced Colorectal Carcinoma (SHORE) | NCT01277406
Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules (2015) 1.25
Epigenetic treatment of solid tumours: a review of clinical trials. Clin Epigenetics (2015) 0.96
Trichostatin A Sensitizes Hepatocellular Carcinoma Cells to Enhanced NK Cell-mediated Killing by Regulating Immune-related Genes. Cancer Genomics Proteomics (2017) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
The fundamental role of epigenetic events in cancer. Nat Rev Genet (2002) 30.05
Revised response criteria for malignant lymphoma. J Clin Oncol (2007) 22.19
Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov (2006) 14.01
Alteration of nucleosome structure as a mechanism of transcriptional regulation. Annu Rev Biochem (1998) 8.86
HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell (2005) 6.00
Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A (2000) 5.53
FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist (2007) 4.95
Histone deacetylase inhibitors in cancer therapy. J Clin Oncol (2009) 4.58
Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther (2003) 3.37
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol (2009) 3.13
The role of histone deacetylases (HDACs) in human cancer. Mol Oncol (2007) 2.72
Clinical studies of histone deacetylase inhibitors. Clin Cancer Res (2009) 2.68
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood (2011) 2.64
Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res (2007) 1.62
Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol (2011) 1.36
Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds? Leukemia (2006) 1.19
A work in progress: the clinical development of histone deacetylase inhibitors. Epigenetics (2008) 1.14
Adenoviral vectors expressing siRNAs for discovery and validation of gene function. Genome Res (2003) 1.09
Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. Int J Oncol (2004) 1.08
HDAC inhibitors and cardiac safety. Clin Cancer Res (2007) 0.98
The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. Br J Haematol (2010) 0.93
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol (2008) 10.91
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2012) 6.49
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol (2010) 6.42
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol (2010) 5.86
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol (2009) 5.45
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res (2009) 4.68
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol (2010) 4.64
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol (2011) 4.53
Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol (2008) 3.41
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol (2013) 3.38
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol (2009) 3.21
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int (2005) 3.06
Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol (2005) 2.99
Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell (2009) 2.85
Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res (2012) 2.81
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol (2013) 2.72
Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol (2013) 2.71
Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res (2009) 2.62
Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res (2007) 2.61
Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. J Clin Oncol (2013) 2.57
Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol (2010) 2.47
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol (2012) 2.33
Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab (2011) 2.32
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncol (2012) 2.31
Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol (2011) 2.14
Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol (2009) 2.11
Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res (2009) 2.04
New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res (2011) 2.01
Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer (2014) 1.93
Targeting CYP17: established and novel approaches in prostate cancer. Curr Opin Pharmacol (2008) 1.85
Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin (2011) 1.68
Envisioning the future of early anticancer drug development. Nat Rev Cancer (2010) 1.67
Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. Clin Cancer Res (2011) 1.64
The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol (2011) 1.55
Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies. Expert Opin Investig Drugs (2011) 1.53
Abiraterone acetate is well tolerated without concomitant use of corticosteroids. J Clin Oncol (2010) 1.51
Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol (2009) 1.50
CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol (2008) 1.49
Induction chemotherapy, cytoreductive surgery and intraoperative hyperthermic pleural irrigation in patients with stage IVA thymoma. Interact Cardiovasc Thorac Surg (2010) 1.49
Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities? J Clin Oncol (2011) 1.48
A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res (2008) 1.47
Clinical benefit of new targeted agents in phase I trials in patients with advanced colorectal cancer. Oncology (2009) 1.47
Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J (2009) 1.46
A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res (2010) 1.42
90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial? Eur J Cancer (2008) 1.39
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Invest New Drugs (2012) 1.38
Ambient light levels and critical care outcomes. J Crit Care (2012) 1.38
Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma. J Thorac Oncol (2012) 1.36
Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors. Am J Surg Pathol (2012) 1.34
Utilizing circulating tumor cells: challenges and pitfalls. Curr Opin Genet Dev (2010) 1.34
Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. J Clin Oncol (2012) 1.33
Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur J Cancer (2010) 1.32
Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nat Rev Clin Oncol (2011) 1.31
Development of therapeutic combinations targeting major cancer signaling pathways. J Clin Oncol (2013) 1.30
Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One (2012) 1.27
External quality assurance of circulating tumor cell enumeration using the CellSearch(®) system: a feasibility study. Cytometry B Clin Cytom (2010) 1.24
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? Drug Discov Today (2009) 1.24
Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. Eur Urol (2013) 1.24
Tumor formation initiated by nondividing epidermal cells via an inflammatory infiltrate. Proc Natl Acad Sci U S A (2010) 1.22
Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res (2011) 1.21
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J Pathol (2013) 1.20
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. J Hematol Oncol (2014) 1.20
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. Cancer Chemother Pharmacol (2013) 1.19
Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer. Mod Pathol (2012) 1.19
Life-expectancy of patients enrolled in phase 1 clinical trials: a systematic review of published prognostic models. Crit Rev Oncol Hematol (2012) 1.18
Combining antiangiogenics to overcome resistance: rationale and clinical experience. Clin Cancer Res (2012) 1.18
Cardiac ankyrin repeat protein, a negative regulator of cardiac gene expression, is augmented in human heart failure. Biochem Biophys Res Commun (2002) 1.17
Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clin Cancer Res (2008) 1.14
Structure and distribution of antennal sensilla of the red imported fire ant. Micron (2003) 1.08
Critical care rehabilitation trials: the importance of 'usual care'. Crit Care (2013) 1.05
Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. Clin Cancer Res (2010) 1.05
Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer. PLoS One (2013) 1.04
Targeting the DNA damage response in oncology: past, present and future perspectives. Curr Opin Oncol (2012) 1.04
The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment. Curr Drug Targets (2011) 1.03